Skip to main
EKSO

EKSO Stock Forecast & Price Target

EKSO Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ekso Bionics Holdings Inc. demonstrated a robust recovery in its financial performance for the third quarter of 2025, with total revenues reaching $4.22 million, reflecting a notable 105% quarter-over-quarter growth compared to $2.06 million in the second quarter. The company also saw a significant improvement in gross margins, which increased to 60.3% from 39.8% in the previous quarter. Additionally, the announcement of a non-binding merger agreement with Applied Digital Cloud may further enhance its operational capabilities and market position, contributing to a favorable outlook for the company's stock.

Bears say

Ekso Bionics Holdings Inc. experienced a revenue miss in the prior quarter, attributed to order delays in enterprise sales totaling $1.5 million, which has contributed to a negative outlook on the stock. The company reported 3Q25 revenues of $4.23 million and a narrower net loss of $0.54 per share, which, while slightly better than consensus estimates, does not indicate a robust financial recovery. Overall, the recent downgrade to a Neutral rating coupled with operational challenges suggests ongoing uncertainties surrounding the company's ability to meet growth expectations in its targeted markets.

EKSO has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ekso Bionics Hlds (EKSO) Forecast

Analysts have given EKSO a Strong Buy based on their latest research and market trends.

According to 2 analysts, EKSO has a Strong Buy consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ekso Bionics Hlds (EKSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.